bms195614 Search Results


bms 195614  (MedChemExpress)
94
MedChemExpress bms 195614
Bms 195614, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bms195614/BMS-195614/bio_rxiv__64898__2026__01__21__700864-260-9-10
Average 94 stars, based on 1 article reviews
bms 195614 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
bms-195614  (MuseChem Chemicals)
N/A
BMS-195614 (Cat No.: I004603) is a potent small-molecule antagonist of the melatonin MT1 and MT2 receptors, widely used to investigate melatonergic signaling pathways. By blocking melatonin binding, it enables researchers to explore regulatory mechanisms involved
   Buy from Supplier
rarγ  (Tocris)
93
Tocris rarγ
a ) Proliferation of cells expressing varying levels of FABP5 was assessed by cell counting. Mean±SD (n=4). **p<0.01, by unpaired t-test vs. e.v. expressing cells. b ) MTT assays in cells treated with vehicle or RA (1 μM, 4 days). Mean±SD (n=4). **p<0.01, by unpaired t-test vs. untreated cells. c ) Representative image (out of 3) of colonies formed in soft agar by NaF lines with varying expression levels of FABP5. See for colony counts. d ) NaF cells (2×10 6 ) stably expressing empty vector or vector encoding FABP5shRNA (shF5-3, ) were transplanted into the mammary fat pad of NCr athymic female mice (n=5). Tumor growth was monitored. Mean ±SEM. e ) MTT assays in NaF cells treated with 16:0 (4 days). Mean±SD (n=4). *p<0.05, **p<0.01 vs. untreated control, #p<0.01 vs. e.v. control. p-values were calculated by unpaired t-test. f ) Cells were treated with 16:0 for 4 days and apoptosis evaluated by FACS analyses. Data from 1 out of 4 experiments are shown. g ) Immunoblots of cleaved caspase 3 in NaF lines treated with 16:0 for 4 days. h ) Representative image (out of 3) of colonies formed in soft agar by NaF cells treated with vehicle (−) or 16:0 (10 μM). **p<0.01 by unpaired t-test. i ) MTT assays in MCF-7 cells overexpressing GFP-FABP5 or GFP control and treated with 16:0 (8 days). Mean±SD (n=4). *p<0.05, **p<0.01 vs. untreated control, #p<0.01 vs. e.v. control. j ) Immunoblots of cleaved PARP in MCF-7 cells overexpressing GFP-FABP5 or GFP control and treated with 16:0 for 8 days. k ) Levels of Chop and Grp78 mRNA in NaF cells treated with varying concentrations of 16:0 for 8 h. Mean ±SD (n=3). *p<0.05, *p<0.01 by unpaired t-test. l ) Levels of Chop and Grp78 mRNA in NaF cells treated with 16:0 for 4 days. m ) Immunoblots of cleaved PARP in NaF cells treated with 16:0 for 4 days in the presence or absence <t>of</t> <t>antagonists</t> for RARα (BMS19614), RARβ (LE135), or <t>RARγ</t> (MM11253) (1 μM each). Immunoblots in panels g, j, and m are representative of 3 independent experiments.
Rarγ, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bms195614/BMS+195614/pmc04662070-149-9-21
Average 93 stars, based on 1 article reviews
rarγ - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
bms 614  (Tocris)
92
Tocris bms 614
a ) Proliferation of cells expressing varying levels of FABP5 was assessed by cell counting. Mean±SD (n=4). **p<0.01, by unpaired t-test vs. e.v. expressing cells. b ) MTT assays in cells treated with vehicle or RA (1 μM, 4 days). Mean±SD (n=4). **p<0.01, by unpaired t-test vs. untreated cells. c ) Representative image (out of 3) of colonies formed in soft agar by NaF lines with varying expression levels of FABP5. See for colony counts. d ) NaF cells (2×10 6 ) stably expressing empty vector or vector encoding FABP5shRNA (shF5-3, ) were transplanted into the mammary fat pad of NCr athymic female mice (n=5). Tumor growth was monitored. Mean ±SEM. e ) MTT assays in NaF cells treated with 16:0 (4 days). Mean±SD (n=4). *p<0.05, **p<0.01 vs. untreated control, #p<0.01 vs. e.v. control. p-values were calculated by unpaired t-test. f ) Cells were treated with 16:0 for 4 days and apoptosis evaluated by FACS analyses. Data from 1 out of 4 experiments are shown. g ) Immunoblots of cleaved caspase 3 in NaF lines treated with 16:0 for 4 days. h ) Representative image (out of 3) of colonies formed in soft agar by NaF cells treated with vehicle (−) or 16:0 (10 μM). **p<0.01 by unpaired t-test. i ) MTT assays in MCF-7 cells overexpressing GFP-FABP5 or GFP control and treated with 16:0 (8 days). Mean±SD (n=4). *p<0.05, **p<0.01 vs. untreated control, #p<0.01 vs. e.v. control. j ) Immunoblots of cleaved PARP in MCF-7 cells overexpressing GFP-FABP5 or GFP control and treated with 16:0 for 8 days. k ) Levels of Chop and Grp78 mRNA in NaF cells treated with varying concentrations of 16:0 for 8 h. Mean ±SD (n=3). *p<0.05, *p<0.01 by unpaired t-test. l ) Levels of Chop and Grp78 mRNA in NaF cells treated with 16:0 for 4 days. m ) Immunoblots of cleaved PARP in NaF cells treated with 16:0 for 4 days in the presence or absence <t>of</t> <t>antagonists</t> for RARα (BMS19614), RARβ (LE135), or <t>RARγ</t> (MM11253) (1 μM each). Immunoblots in panels g, j, and m are representative of 3 independent experiments.
Bms 614, supplied by Tocris, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bms195614/BMS+195614/pmc11134608-29-0-2
Average 92 stars, based on 1 article reviews
bms 614 - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier
antagonists for rarα  (Santa Cruz Biotechnology)
90
Santa Cruz Biotechnology antagonists for rarα
a ) Proliferation of cells expressing varying levels of FABP5 was assessed by cell counting. Mean±SD (n=4). **p<0.01, by unpaired t-test vs. e.v. expressing cells. b ) MTT assays in cells treated with vehicle or RA (1 μM, 4 days). Mean±SD (n=4). **p<0.01, by unpaired t-test vs. untreated cells. c ) Representative image (out of 3) of colonies formed in soft agar by NaF lines with varying expression levels of FABP5. See for colony counts. d ) NaF cells (2×10 6 ) stably expressing empty vector or vector encoding FABP5shRNA (shF5-3, ) were transplanted into the mammary fat pad of NCr athymic female mice (n=5). Tumor growth was monitored. Mean ±SEM. e ) MTT assays in NaF cells treated with 16:0 (4 days). Mean±SD (n=4). *p<0.05, **p<0.01 vs. untreated control, #p<0.01 vs. e.v. control. p-values were calculated by unpaired t-test. f ) Cells were treated with 16:0 for 4 days and apoptosis evaluated by FACS analyses. Data from 1 out of 4 experiments are shown. g ) Immunoblots of cleaved caspase 3 in NaF lines treated with 16:0 for 4 days. h ) Representative image (out of 3) of colonies formed in soft agar by NaF cells treated with vehicle (−) or 16:0 (10 μM). **p<0.01 by unpaired t-test. i ) MTT assays in MCF-7 cells overexpressing GFP-FABP5 or GFP control and treated with 16:0 (8 days). Mean±SD (n=4). *p<0.05, **p<0.01 vs. untreated control, #p<0.01 vs. e.v. control. j ) Immunoblots of cleaved PARP in MCF-7 cells overexpressing GFP-FABP5 or GFP control and treated with 16:0 for 8 days. k ) Levels of Chop and Grp78 mRNA in NaF cells treated with varying concentrations of 16:0 for 8 h. Mean ±SD (n=3). *p<0.05, *p<0.01 by unpaired t-test. l ) Levels of Chop and Grp78 mRNA in NaF cells treated with 16:0 for 4 days. m ) Immunoblots of cleaved PARP in NaF cells treated with 16:0 for 4 days in the presence or absence <t>of</t> <t>antagonists</t> for RARα (BMS19614), RARβ (LE135), or <t>RARγ</t> (MM11253) (1 μM each). Immunoblots in panels g, j, and m are representative of 3 independent experiments.
Antagonists For Rarα, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bms195614/BMS+195614/pm32638255-38-0-13
Average 90 stars, based on 1 article reviews
antagonists for rarα - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
bms 195614  (Cayman Chemical)
N/A
BMS 195614 is a neutral retinoic acid receptor RAR α selective antagonist K 2 5 nM It antagonizes agonist induced coactivator recruitment and moderately decreases SMRT binding to RAR but does not significantly affect nuclear
   Buy from Supplier
bms 195614  (Biosynth Carbosynth)
N/A
   Buy from Supplier
bms 195614  (TargetMol)
N/A
   Buy from Supplier
bms 195614  (BOC Sciences)
N/A
BMS 195614 is a neutral RAR α-selective antagonist (Ki = 2.5 nM) and exhibits no significant effect on nuclear receptor corepressor (NCoR) binding. BMS 195614 moderately decreases SMRT binding to RAR and agonist-induced coactivator (CoA)
   Buy from Supplier
bms 195614  (Aladdin Scientific Corporation)
N/A
BMS 195614 is a selective neutral RARα inhibitor and exhibits no significant effect on NCoR binding. The compound potentially decreases agonist-induced coactivator recruitment and SMRT binding to RAR. RARs, or Retinoic Acid Receptors, are nuclear
   Buy from Supplier

Image Search Results


a ) Proliferation of cells expressing varying levels of FABP5 was assessed by cell counting. Mean±SD (n=4). **p<0.01, by unpaired t-test vs. e.v. expressing cells. b ) MTT assays in cells treated with vehicle or RA (1 μM, 4 days). Mean±SD (n=4). **p<0.01, by unpaired t-test vs. untreated cells. c ) Representative image (out of 3) of colonies formed in soft agar by NaF lines with varying expression levels of FABP5. See for colony counts. d ) NaF cells (2×10 6 ) stably expressing empty vector or vector encoding FABP5shRNA (shF5-3, ) were transplanted into the mammary fat pad of NCr athymic female mice (n=5). Tumor growth was monitored. Mean ±SEM. e ) MTT assays in NaF cells treated with 16:0 (4 days). Mean±SD (n=4). *p<0.05, **p<0.01 vs. untreated control, #p<0.01 vs. e.v. control. p-values were calculated by unpaired t-test. f ) Cells were treated with 16:0 for 4 days and apoptosis evaluated by FACS analyses. Data from 1 out of 4 experiments are shown. g ) Immunoblots of cleaved caspase 3 in NaF lines treated with 16:0 for 4 days. h ) Representative image (out of 3) of colonies formed in soft agar by NaF cells treated with vehicle (−) or 16:0 (10 μM). **p<0.01 by unpaired t-test. i ) MTT assays in MCF-7 cells overexpressing GFP-FABP5 or GFP control and treated with 16:0 (8 days). Mean±SD (n=4). *p<0.05, **p<0.01 vs. untreated control, #p<0.01 vs. e.v. control. j ) Immunoblots of cleaved PARP in MCF-7 cells overexpressing GFP-FABP5 or GFP control and treated with 16:0 for 8 days. k ) Levels of Chop and Grp78 mRNA in NaF cells treated with varying concentrations of 16:0 for 8 h. Mean ±SD (n=3). *p<0.05, *p<0.01 by unpaired t-test. l ) Levels of Chop and Grp78 mRNA in NaF cells treated with 16:0 for 4 days. m ) Immunoblots of cleaved PARP in NaF cells treated with 16:0 for 4 days in the presence or absence of antagonists for RARα (BMS19614), RARβ (LE135), or RARγ (MM11253) (1 μM each). Immunoblots in panels g, j, and m are representative of 3 independent experiments.

Journal: Nature communications

Article Title: Saturated fatty-acids regulate retinoic acid signaling and suppress tumorigenesis by targeting fatty-acid-binding protein 5

doi: 10.1038/ncomms9794

Figure Lengend Snippet: a ) Proliferation of cells expressing varying levels of FABP5 was assessed by cell counting. Mean±SD (n=4). **p<0.01, by unpaired t-test vs. e.v. expressing cells. b ) MTT assays in cells treated with vehicle or RA (1 μM, 4 days). Mean±SD (n=4). **p<0.01, by unpaired t-test vs. untreated cells. c ) Representative image (out of 3) of colonies formed in soft agar by NaF lines with varying expression levels of FABP5. See for colony counts. d ) NaF cells (2×10 6 ) stably expressing empty vector or vector encoding FABP5shRNA (shF5-3, ) were transplanted into the mammary fat pad of NCr athymic female mice (n=5). Tumor growth was monitored. Mean ±SEM. e ) MTT assays in NaF cells treated with 16:0 (4 days). Mean±SD (n=4). *p<0.05, **p<0.01 vs. untreated control, #p<0.01 vs. e.v. control. p-values were calculated by unpaired t-test. f ) Cells were treated with 16:0 for 4 days and apoptosis evaluated by FACS analyses. Data from 1 out of 4 experiments are shown. g ) Immunoblots of cleaved caspase 3 in NaF lines treated with 16:0 for 4 days. h ) Representative image (out of 3) of colonies formed in soft agar by NaF cells treated with vehicle (−) or 16:0 (10 μM). **p<0.01 by unpaired t-test. i ) MTT assays in MCF-7 cells overexpressing GFP-FABP5 or GFP control and treated with 16:0 (8 days). Mean±SD (n=4). *p<0.05, **p<0.01 vs. untreated control, #p<0.01 vs. e.v. control. j ) Immunoblots of cleaved PARP in MCF-7 cells overexpressing GFP-FABP5 or GFP control and treated with 16:0 for 8 days. k ) Levels of Chop and Grp78 mRNA in NaF cells treated with varying concentrations of 16:0 for 8 h. Mean ±SD (n=3). *p<0.05, *p<0.01 by unpaired t-test. l ) Levels of Chop and Grp78 mRNA in NaF cells treated with 16:0 for 4 days. m ) Immunoblots of cleaved PARP in NaF cells treated with 16:0 for 4 days in the presence or absence of antagonists for RARα (BMS19614), RARβ (LE135), or RARγ (MM11253) (1 μM each). Immunoblots in panels g, j, and m are representative of 3 independent experiments.

Article Snippet: GW1516 (GW), TTNPB, and antagonists for RARα, RARβ and RARγ (BMS 195614, LE 135 and MM 11253, respectively) were purchased from Tocris Biosciences.

Techniques: Expressing, Cell Counting, Stable Transfection, Plasmid Preparation, Control, Western Blot

a ) Concentrations of 16:0 in tumors of mice fed denoted diets. Mean±SD (n=6). **p<0.01 by unpaired t-test vs. chow control. b ) NaF cells (2×10 6 ) were transplanted into the mammary fat pad of NCr athymic female mice fed denoted diets and tumor growth was monitored. Mean±SD (n=6). **p<0.01 by unpaired t-test vs. chow control. c ), d ) mRNAs for PPARβ/δ (c) or RAR target genes (d) in mice fed denoted diets. Mean±SD (n=6). *p<0.05, **p<0.01 calculated by unpaired t-test. e ) Immunoblots demonstrating expression of PDPK1 and RARβ in tumors of mice fed denoted diets. Blots are representative data from 3 individual mice per group. f ) Immunohistochemistry analyses demonstrating expression of Ki67 and cleaved caspase 3 in tumors of mice fed denoted diets. Representative images out of three tumors per group are shown. Magnification 400x, scale bars represent 50 μm. g ) A model illustrating the mechanism by which SLCFA and ULCFA regulate RA signaling. Left: SLCFA compete with RA and other PPARβ/δ ligands for binding FABP5, divert RA to RAR and inhibit PPARβ/δ activation. Right: ULCFA bind to FABP5 and divert RA to RAR. ULCFA are delivered to PPARβ/δ by FABP5 and activate it.

Journal: Nature communications

Article Title: Saturated fatty-acids regulate retinoic acid signaling and suppress tumorigenesis by targeting fatty-acid-binding protein 5

doi: 10.1038/ncomms9794

Figure Lengend Snippet: a ) Concentrations of 16:0 in tumors of mice fed denoted diets. Mean±SD (n=6). **p<0.01 by unpaired t-test vs. chow control. b ) NaF cells (2×10 6 ) were transplanted into the mammary fat pad of NCr athymic female mice fed denoted diets and tumor growth was monitored. Mean±SD (n=6). **p<0.01 by unpaired t-test vs. chow control. c ), d ) mRNAs for PPARβ/δ (c) or RAR target genes (d) in mice fed denoted diets. Mean±SD (n=6). *p<0.05, **p<0.01 calculated by unpaired t-test. e ) Immunoblots demonstrating expression of PDPK1 and RARβ in tumors of mice fed denoted diets. Blots are representative data from 3 individual mice per group. f ) Immunohistochemistry analyses demonstrating expression of Ki67 and cleaved caspase 3 in tumors of mice fed denoted diets. Representative images out of three tumors per group are shown. Magnification 400x, scale bars represent 50 μm. g ) A model illustrating the mechanism by which SLCFA and ULCFA regulate RA signaling. Left: SLCFA compete with RA and other PPARβ/δ ligands for binding FABP5, divert RA to RAR and inhibit PPARβ/δ activation. Right: ULCFA bind to FABP5 and divert RA to RAR. ULCFA are delivered to PPARβ/δ by FABP5 and activate it.

Article Snippet: GW1516 (GW), TTNPB, and antagonists for RARα, RARβ and RARγ (BMS 195614, LE 135 and MM 11253, respectively) were purchased from Tocris Biosciences.

Techniques: Control, Western Blot, Expressing, Immunohistochemistry, Binding Assay, Activation Assay